Develops therapies for dermatological disorders and orphan diseases, focusing on novel treatments for conditions such as eczema and psoriasis.
Hoth Therapeutics, Inc., headquartered in New York, New York, is a pioneering clinical-stage biopharmaceutical company dedicated to addressing unmet medical needs through innovative therapies. Founded in 2017, Hoth Therapeutics focuses on developing a diverse pipeline of treatments targeting a range of conditions. Among its key initiatives, the company is advancing HT-001, a topical formulation designed to alleviate rash and skin disorders associated with tyrosine kinase epidermal growth factor receptor inhibitor therapy. Additionally, Hoth Therapeutics is developing HT-KIT for mast-cell derived cancers and anaphylaxis, HT-ALZ for Alzheimer's and neuroinflammatory diseases, and HT-003 for inflammatory bowel diseases, acne, and psoriasis.
Further expanding its portfolio, Hoth Therapeutics is progressing with HT-004 for asthma and allergies via inhalational administration, HT-006 for lung diseases resulting from bacterial infections, and HT-002, a novel peptide targeting COVID-19. The company's innovative approach also includes the BioLexa Platform, currently in Phase I clinical trials for treating eczema, and HT-005 for lupus treatment. Collaborative efforts underscore Hoth Therapeutics' commitment to advancing medical science, with strategic partnerships and license agreements in place with esteemed institutions such as George Washington University, University of Maryland, and Weill Cornell Medicine.
Driven by a mission to transform patient outcomes, Hoth Therapeutics leverages its proprietary drug compound platforms and robust research collaborations to pioneer new treatments. With a strong foundation in New York, Hoth Therapeutics continues to expand its therapeutic pipeline and pursue groundbreaking solutions to complex medical challenges worldwide.